Please ensure Javascript is enabled for purposes of website accessibility

Ionis Pharmaceuticals Inc Turns a Profit With Other Drugmakers' Money

By Brian Orelli, PhD - Mar 1, 2017 at 3:56PM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

Cash from partners are paying the biotech's bills as its pipeline advances.

Ionis Pharmaceuticals (IONS -1.08%) reported fourth-quarter earnings on Tuesday. The biotech has two drugs on the market, but given Kynamro's low sales and the fact that spinal muscular atrophy drug Spinraza only launched in late December, most of the revenue came from partners who have licensed its drugs. Nevertheless, those payments helped drive Ionis into the black in the fourth quarter.

Ionis Pharmaceuticals results: The raw numbers

Metric

Q4 2016

Q4 2015

Year-Over-Year Change

Revenue

$160.3 million

$51.6 million

211%

Income from operations

$41.1 million

($62.9 million)

N/A

Earnings per share

$0.21

($0.59)

N/A

Data source: Ionis Pharmaceuticals.

Scientists working in a lab

Image source: Getty Images.

What happened with Ionis Pharmaceuticals this quarter?

  • The biggest event of the quarter happened just days before the books closed, when Spinraza was approved by the Food and Drug Administration in late December, triggering a milestone payment from partner Biogen (BIIB 1.34%).
  • Ionis had good news on the pipeline front in December, as well, when it reported positive data from the COMPASS phase 3 trial testing volanesorsen in patients with severe hypertriglyceridemia. The drug produced a mean reduction in triglycerides of 71.2% from baseline compared to a 0.9% reduction for patients who received placebo.
  • In January, after the books closed, Ionis signed a deal with Novartis (NVS 0.71%) to develop and commercialize two early stage cardiovascular disease drugs, AKCEA-APO(a)-LRx and AKCEA-APOCIII-LRx. The deal provides near-term payments of $225 million, plus potential milestone and royalty payments down the road.
  • Also in January, partner Bayer decided to advance IONIS-FXIRx into a phase 2b trial in patients with end-stage renal disease on hemodialysis, which Ionis will conduct. Bayer also chose to license a next-generation drug, IONIS-FXI-LRx, which, combined with the advancement of IONIS-FXIRx, triggered a $75 million milestone payment.

What management had to say

Biogen is in charge of the Spinraza launch, but Lynne Parshall, Ionis' chief operating officer, likes what she's seen so far:

"We are pleased with the urgency with which Biogen is undertaking this launch. For example, we received FDA approval just before the holidays on December 23. And by December 26, there were already teams in the field working with physicians to ensure the patients had access to Spinraza as rapidly as possible."

Ionis' chief financial officer Beth Hougen pointed out the economics on sales of Spinraza: "We earn tiered royalties on Spinraza sales. This means that, as Spinraza sales grow, so will our portion of those sales. The revenue we earned from these royalties is nearly all profit to us."

Looking forward

It's going to be a data-packed beginning of the year for Ionis with a readout from the phase 3 APPROACH study testing volanesorsen in patients with familial chylomicronemia syndrome expected in March. A little while later, sometime in the second quarter, Ionis will present data from the phase 3 NEURO-TTR study of IONIS-TTRRx in patients with familial amyloid polyneuropathy.

With the potential for both those drugs to get approved if the phase 3 trials are successful, Ionis is restocking the pipeline with plans to add three to five new drugs to the pipeline this year.

Adding the milestone payments to the Spinraza royalty payments, management thinks it can be breakeven or profitable at the operating line on a pro forma basis in 2017, which would allow the company to be cash-flow positive.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

Ionis Pharmaceuticals, Inc. Stock Quote
Ionis Pharmaceuticals, Inc.
IONS
$37.56 (-1.08%) $0.41
Novartis AG Stock Quote
Novartis AG
NVS
$84.77 (0.71%) $0.60
Biogen Inc. Stock Quote
Biogen Inc.
BIIB
$205.23 (1.34%) $2.72

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning analyst team.

Stock Advisor Returns
319%
 
S&P 500 Returns
112%

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 06/29/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.